Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02591082 · ClinicalTrials.gov registry record
Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter
A clinical trial, sponsored by RenovoRx.
- Completed
- Registry status
- 25
- Enrollment target
NCT02591082: Completed study, sponsored by RenovoRx.
NCT02591082 is a clinical trial that has completed, run by RenovoRx. The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02591082 has completed, sponsored by RenovoRx.
- COMPLETED
- Registry status
- 25 participants
- Enrollment target
Study Summary
This is an observational study to assess patient survival and clinical outcomes after the RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.
Primary Outcome
Duration of survival in patients diagnosed with pancreatic cancer who undergo intra-arterial delivery of chemotherapeutic agents to the pancreas
Interventions
- DEVICE RenovoCath™ R120 Catheter
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-12 |
| Est. Completion | 2021-02-26 |
What the finished NCT02591082 record still lists
NCT02591082 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 25 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which RenovoCath™ R120 Catheter is the first listed.
NCT02591082 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02591082 about?
NCT02591082 is a clinical study titled "Intra-Arterial Treatment of Pancreatic Cancer Using the RenovoCath™ RC120 Catheter". This is an observational study to assess patient survival and clinical outcomes after the RenovoCath™ RC120 catheter is used to deliver chemotherapeutic agents to pancreatic tumors.
What is the current status of trial NCT02591082?
This trial is currently completed. The enrollment target is 25 participants. The study started on 2015-12. Estimated completion is 2021-02-26.
What interventions are being tested in trial NCT02591082?
The interventions under investigation include: RenovoCath™ R120 Catheter (DEVICE).
Who is sponsoring clinical trial NCT02591082?
This trial is sponsored by RenovoRx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia